Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort study

V. Dvořák, M. Petráš, V. Dvořák, D. Lomozová, P. Dlouhý, I. Králová Lesná, R. Pilka

. 2024 ; 20 (1) : 2343552. [pub] 20240509

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc24013275

The main aim of our study was to investigate the specific contribution of a 9-valent human papillomavirus vaccine (9vHPV) to the recurrence risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women vaccinated post-excision. Therefore, we conducted a retrospective monocentric cohort study in women aged 22-49 years undergoing conization between 2014 and 2023. The 9vHPV-vaccinated women were matched to unvaccinated women for age and follow-up duration in a 1:2 ratio to eliminate allocation bias. The risk of CIN2+ recurrence was estimated by the incidence rate ratio using Poisson regression with adjustment for comorbidities, smoking status, nulliparity, CIN grade, positive cone margin, and HPV genotypes. The CIN2+ recurrence rates in 147 women enrolled in the analysis were 18 and 2 cases per 100,000 person-days for unvaccinated and vaccinated women, respectively, during a mean follow-up period of 30 months (±22 months). A reduction in CIN2+ recurrences by 90% (95% confidence interval: 12-99%) was documented in 9vHPV-vaccinated participants compared to women undergoing only surgical excision. Moreover, vaccinated women with a positive cone margin showed a 42% (though non-significant) reduction in relapse (p = .661). Full post-conization vaccination with the 9vHPV contributed to an additional reduction in the risk of CIN2+ recurrence. This finding is consistent with current knowledge and suggests a high adjuvant effect of the 9vHPV vaccine.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013275
003      
CZ-PrNML
005      
20240905134159.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/21645515.2024.2343552 $2 doi
035    __
$a (PubMed)38723789
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dvořák, Vladimír $u Center of Ambulatory Gynecology and Primary Care, Brno, Czech Republic $u Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
245    10
$a Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort study / $c V. Dvořák, M. Petráš, V. Dvořák, D. Lomozová, P. Dlouhý, I. Králová Lesná, R. Pilka
520    9_
$a The main aim of our study was to investigate the specific contribution of a 9-valent human papillomavirus vaccine (9vHPV) to the recurrence risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women vaccinated post-excision. Therefore, we conducted a retrospective monocentric cohort study in women aged 22-49 years undergoing conization between 2014 and 2023. The 9vHPV-vaccinated women were matched to unvaccinated women for age and follow-up duration in a 1:2 ratio to eliminate allocation bias. The risk of CIN2+ recurrence was estimated by the incidence rate ratio using Poisson regression with adjustment for comorbidities, smoking status, nulliparity, CIN grade, positive cone margin, and HPV genotypes. The CIN2+ recurrence rates in 147 women enrolled in the analysis were 18 and 2 cases per 100,000 person-days for unvaccinated and vaccinated women, respectively, during a mean follow-up period of 30 months (±22 months). A reduction in CIN2+ recurrences by 90% (95% confidence interval: 12-99%) was documented in 9vHPV-vaccinated participants compared to women undergoing only surgical excision. Moreover, vaccinated women with a positive cone margin showed a 42% (though non-significant) reduction in relapse (p = .661). Full post-conization vaccination with the 9vHPV contributed to an additional reduction in the risk of CIN2+ recurrence. This finding is consistent with current knowledge and suggests a high adjuvant effect of the 9vHPV vaccine.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    12
$a dysplazie děložního hrdla $x prevence a kontrola $x virologie $7 D002578
650    12
$a infekce papilomavirem $x prevence a kontrola $7 D030361
650    12
$a vakcíny proti papilomavirům $x aplikace a dávkování $x imunologie $7 D053918
650    12
$a nádory děložního čípku $x prevence a kontrola $x virologie $7 D002583
650    _2
$a mladý dospělý $7 D055815
650    12
$a lokální recidiva nádoru $x prevence a kontrola $7 D009364
650    _2
$a konizace děložního čípku $x metody $7 D019092
650    _2
$a vakcinace $7 D014611
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Petráš, Marek $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000329131736
700    1_
$a Dvořák, Vladimír $u Center of Ambulatory Gynecology and Primary Care, Brno, Czech Republic
700    1_
$a Lomozová, Danuše $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Dlouhý, Pavel $u Department of Hygiene, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Králová Lesná, Ivana $u Laboratory for Atherosclerosis Research, Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Anesthesia and Intensive Medicine, First Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic
700    1_
$a Pilka, Radovan $u Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
773    0_
$w MED00181409 $t Human vaccines & immunotherapeutics $x 2164-554X $g Roč. 20, č. 1 (2024), s. 2343552
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38723789 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134153 $b ABA008
999    __
$a ok $b bmc $g 2143227 $s 1225141
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 20 $c 1 $d 2343552 $e 20240509 $i 2164-554X $m Human vaccines & immunotherapeutics $n Hum Vaccin Immunother $x MED00181409
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options